Vertex Pharmaceuticals Incorporated

NASDAQ:VRTX

Biotechnology

Healthcare
$536.45 -1.40%

-$6.43 today

Market cap
$136.01B
Beta
0.31
P/E (TTM)
26.5
EPS (TTM)
$17.07
52W Low $362.50High $507.92

Volume 1.29M

Average 1.26M

VRTX Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX

Common Stock · Q3 FY2026 · quarter ended Sep 2026

Common stock rises 10040.0% from a year ago

Common stock stood at $253.5M at the end of Q3 FY2026, up 10040.0% from a year earlier and up 10040.0% from the prior quarter. Over 3 fiscal years it compounded at -1.3% a year.

Context

  • Common stock amounted to 0.8% of total assets at the end of Q3 FY2026, up 0.8 pp from a year earlier.
  • Common stock increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +10040.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$253.5M+10040.0% QoQ
Last fiscal yearDec 2025
$2.5M-3.8% YoY
Year agoSep 2025
$2.5M+10040.0% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10040.0%——
1 year-3.8%——
3-year CAGR-1.3%——
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
2.5M USD
Year-over-year change
-3.8%
4-year CAGR
+0.0%

Common Stock vs competitors

How VRTX compares with its peers on the latest reported figures

  • VRTX's Sep 2026 common stock of $253.5M is the highest of the 11 companies compared; the peer median is $124K.
  • Its year-over-year change of +10040.0% is the highest of 11, against a peer median of +3.6%.
  • Common stock amounts to 0.8% of total assets for VRTX, versus a peer median of 0.0%.
VRTX Competitors Peer median
Common Stock for VRTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VRTXVertex Pharmaceuticals IncorporatedSep 2026$253.5M +10040.0%-1.3%0.8%
CRSPCRISPR Therapeutics AGSep 2026$3.15M +4.5%+8.1%0.1%
ALNYAlnylam Pharmaceuticals, Inc.Jun 2026$1.34M +2.1%+2.2%0.0%
BEAMBeam Therapeutics Inc.Jun 2026$1.03M +2.5%+12.6%0.1%
BBIOBridgeBio Pharma, Inc.Jun 2026$206K +4.0%+8.8%0.0%
IONSIonis Pharmaceuticals, Inc.Sep 2026$166K +3.1%+4.7%0.0%
PTCTPTC Therapeutics, Inc.Jun 2026$82K +5.1%+3.6%0.0%
NTLAIntellia Therapeutics, Inc.Mar 2026$12K +20.0%+10.1%0.0%
SRPTSarepta Therapeutics, Inc.Mar 2026$11K +10.0%+6.9%0.0%
RAREUltragenyx Pharmaceutical Inc.Mar 2026$0 -100.0%—0.0%
BMRNBioMarin Pharmaceutical Inc.Sep 2026-$10.66B -5550620.8%+1.1%0.1%
Peer median (excluding VRTX) $124K+3.6%+6.9%0.0%

Competitors are the stored peer set for VRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents6.8B10.5B10.37B4.57B5.09B
Short-term Investments729.9M274.5M849.2M1.55B1.52B
Net Receivables1.14B1.44B1.56B1.61B2.05B
Inventory353.1M460.6M738.8M1.21B1.69B
Other Current Assets103.7M121.9M86.1M206.5M748.6M
Total Current Assets9.56B13.23B14.14B9.6B11.2B
Property, Plant & Equipment (Net)1.42B1.46B1.45B2.58B3.08B
Goodwill1B1.09B1.09B1.09B1.09B
Intangible Assets400M603.6M839.9M825.9M424.2M
Long-term Investments0112.2M2.5B5.11B5.81B
Tax Assets934.5M1.25B1.81B2.33B3.4B
Other Non-current Assets110.8M409.6M895.3M999.3M1.14B
Total Non-current Assets3.87B4.92B8.59B12.94B14.94B
Total Assets13.43B18.15B22.73B22.53B26.14B
Account Payables195M303.9M364.9M413M461.7M
Short-term Debt00092.3M82.8M
Tax Payables211.3M123.3M99.5M161.1M0
Deferred Revenue171.7M159.6M170.3M206.8M171.8M
Other Current Liabilities16.5M62.5M50.7M2.5B2.75B
Total Current Liabilities2.14B2.74B3.55B3.56B3.86B
Long-term Debt00001.85B
Deferred Tax Liabilities00001.31B
Deferred Revenue (Non-current)00000
Other Non-current Liabilities303.3M685.8M877.7M901.8M(1.49B)
Total Non-current Liabilities1.19B1.5B1.6B2.56B3.62B
Total Liabilities3.33B4.24B5.15B6.12B7.48B
Common Stock2.5M2.6M2.6M2.6M2.5M
Retained Earnings3.2B6.52B10.14B9.61B13.56B
Accumulated OCI15.9M800K(14.3M)127.8M(15.9M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity10.1B13.91B17.58B16.41B18.67B
Total Debt967.4M899.7M808.4M1.75B3.88B
Net Debt(5.83B)(9.6B)(9.56B)(2.82B)(1.21B)

Vertex Pharmaceuticals Incorporated

NASDAQ:VRTX

Intrinsic Alpha fair value

Locked

Current Price

$536.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.